Dermatology
Feature
European agency supports marketing of abrocitinib for atopic dermatitis
The JAK inhibitor is under review at the FDA for the same indication.
Conference Coverage
Fecal microbiota transplants may improve resistance to melanoma immunotherapy
“The big question that’s lacking is why and how does FMT work, and how can we make the response better?”
Latest News
FDA OKs iPLEDGE change for gender-neutral language
In recent years, dermatologists and others have advocated for the change, hoping to make the process more inclusive and less intrusive for their...
From the Journals
Study of biologics’ impact on psoriasis-to-PsA transition contradicts previous findings
Differing patient selection criteria and other biases may be why results from a large EHR administrative database study contradict those from...
Conference Coverage
PDT for actinic keratoses continues to be refined
Daylight PDT, provides 80%-90% clearance of thin AKs, lower clearance of thick AKs, and is a nearly pain-free procedure because of continuous...
Conference Coverage
In atopic dermatitis trial, abrocitinib offers faster itch relief than dupilumab
The primary endpoint for pruritus at 2 weeks was reached by nearly twice as many patients randomly assigned to abrocitinib.
Conference Coverage
JAK inhibitor provides impressive hair growth for patients with alopecia areata
There was a clear dose effect; hair growth increased more quickly with the 4-mg dose of baricitinib than with the 2-mg dose.
Conference Coverage
Ruxolitinib cream meets primary endpoints in phase 3 vitiligo trial
These findings not only include substantial clinical efficacy but good tolerability with “no serious treatment-related adverse events.”
Conference Coverage
COVID-19: Two more cases of mucosal skin ulcers reported in male teens
Irish
Conference Coverage
Nonsteroidal topical found effective for psoriasis in 52-week study
“This is likely to be very useful in patients who are looking for a topical therapy for skin folds or the face, where there is a need for well-...
Conference Coverage
Oteseconazole promising for recurrent yeast infections
Oteseconazole was superior to fluconazole/placebo in the proportion of subjects with at least one culture-verified acute vulvovaginal candidiasis...